CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie’s first-in-class, orally available small molecule that targets ...

Financial Performance - The net loss for the three months ended September 30, 2025, was approximately $5.1 million, compared to a net loss of $4.2 million for the same period in 2024, reflecting an increase of $900,000 [100]. - Total operating expenses for the three months ended September 30, 2025, were approximately $5.3 million, up from $4.1 million in 2024, representing a net increase of approximately $1.2 million [101]. - The Company reported an accumulated deficit of approximately $357.3 million as of September 30, 2025 [107]. Research and Development - Research and development expenses increased to approximately $2.9 million for the three months ended September 30, 2025, from $2.0 million in 2024, an increase of approximately $946,000 [102]. - The Phase 2 study of bezisterim for Parkinson's Disease was completed in December 2022, with 45 patients randomized in a 1:1 ratio to receive either placebo or bezisterim [92]. - The Company is finalizing the protocol design for a Phase 3 study of BIV201, targeting a broader ascites patient population [96]. - The unplanned exclusion of patients in the Alzheimer's Disease trial left it underpowered for primary endpoints, with only 81 patients remaining in the Modified Intent to Treat population [98]. Funding and Capital - The Company received a clinical trial grant of $13.1 million from the U.S. Department of Defense in April 2024 for the Long COVID program [94]. - As of September 30, 2025, the Company had working capital of approximately $24.4 million and cash and cash equivalents totaling approximately $25.0 million [107]. - The Company closed an underwritten public offering of 5,620,000 units at $2.00 per unit, resulting in net proceeds of approximately $10.5 million [110]. - An additional 380,000 pre-funded units were sold at $1.999 per unit, with each pre-funded warrant immediately exercisable [110]. - The underwriter exercised its over-allotment option, purchasing an additional 667,300 warrants [110]. - Each warrant is exercisable at an exercise price of $2.50 per share and expires five years from the date of issuance [110]. Accounting and Compliance - There were no significant changes to the Company's critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2025 [111]. - Recent accounting pronouncements were determined to be either not applicable or expected to have minimal impact on the balance sheets or statement of operations [112]. - The Company did not identify any market risk disclosures applicable to smaller reporting companies [113]. Revenue Generation - The Company has not generated any revenue and does not expect to do so in the foreseeable future, relying on ongoing development and financing efforts [108].

Financial Data and Key Metrics Changes - The company reported a total of 7,535,080 shares of common stock issued and outstanding as of the record date [6] - Approximately 45.35% of the outstanding common stock was represented at the meeting, with 3,417,857 shares entitled to vote [21] - The Auditor Ratification Proposal received 3,245,049 votes in favor, representing approximately 86.57% of shares present or by proxy [21] Business Line Data and Key Metrics Changes - The meeting included proposals for the election of six directors and the ratification of the independent auditor, indicating a focus on governance and oversight [11][15] Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on governance through the election of directors and the ratification of auditors, which is essential for maintaining investor confidence and regulatory compliance [11][15] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The 2019 Omnibus Equity Incentive Plan was amended to increase the number of shares authorized for issuance to 3 million, reflecting a strategy to incentivize employees and align their interests with shareholders [17] Summary of Q&A Session - There were no questions or answers recorded during this meeting, as the focus was primarily on voting and procedural matters

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of BioVie Inc., urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Shareholders who acquired BioVie stock on or before December 7, 2022, may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees [2]. Group 2: Importance of Shareholder Participation - Active shareholder involvement can lead to improved company policies, practices, and oversight, ultimately enhancing shareholder value [3]. Group 3: Firm's Background and Experience - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Points - BioVie is a company listed on NASDAQ under the ticker BIVI, and the event features a presentation by Cuong Do, the President and CEO of BioVie [1] - The event includes a Q&A session where participants can submit questions via the Zoom platform [1] Company Overview - Cuong Do is leading the presentation for BioVie, indicating a focus on engaging with investors and stakeholders [3]

BioVie (NasdaqCM:BIVI) Update Summary Company Overview - **Company**: BioVie Inc. (Ticker: BIVI) - **Industry**: Biotechnology - **Focus**: Development of therapeutics for neurodegenerative diseases and conditions related to inflammation Key Points and Arguments Clinical Trials and Drug Development - **Parkinson's Disease Trial**: - Currently in Phase II, with enrollment expected to be completed by 2025 - Top-line data readout projected for April-May 2026 [5][7] - Drug candidate bezisterone shows promise in improving muscle control and reducing inflammation [8][15] - **Long COVID Trial**: - Phase II trial underway, with good enrollment progress - Expected to provide guidance on full enrollment within a month [6][24] - A $13 million grant received to test therapeutic effects on CNS symptoms of long COVID [28] - **Ascites Treatment**: - Phase III protocol submitted to the FDA, awaiting feedback [6][34] - Drug candidate BIV201 shows a 50% reduction in dermatitis volume in Phase 2a trial [33] - Expected annual sales for BIV201 estimated between $1.6 billion and $2 billion in the U.S. [37][40] Mechanism of Action - **Bezisterone**: - Modulates TNF alpha production, a key regulator of inflammation [8][9] - Demonstrated neuroprotective properties in preclinical studies [16][18] - Potential to address both Parkinson's and Alzheimer's diseases by reducing inflammation and improving neuronal health [71] Market Potential - **Parkinson's Market**: - Approximately 1 million patients in the U.S. - Estimated annual sales potential of $3 billion to $5 billion with 10% market penetration [36][37] - **Ascites Market**: - Significant unmet need with no current approved therapies - Estimated annual sales potential of $1.6 billion to $2 billion in the U.S. [37][40] Financial Position - **Cash Runway**: - Sufficient cash to fund operations through 2026, covering the timelines for ongoing trials [7][38] - Actively seeking to raise $25 million to fund Phase III trials for ascites [35] Regulatory and Legal Considerations - **FDA Interaction**: - Anticipated to receive no comments on the Phase III protocol for ascites, allowing progression to the next trial phase [40] - **Class Action Lawsuit**: - Currently in the discovery phase, not seen as a significant drain on resources [60][61] Strategic Partnerships - **Pharmaceutical Partnerships**: - Ongoing discussions with major pharmaceutical companies, with interest in the novel mechanism of action [56] - Expectation to out-license or be acquired upon demonstrating positive trial data [56] Additional Insights - **Long COVID Awareness**: - Significant number of Americans suffering from long COVID, with no effective treatments currently available [24][25] - **Market Dynamics**: - The biotechnology sector has faced challenges in capital raising, but there are signs of improvement [46][47] - **Future Development**: - Plans to develop a once-daily formulation of bezisterone post-trial completion [48][49] This summary encapsulates the critical developments and strategic outlook for BioVie, highlighting its innovative approaches to treating significant health conditions and the potential market opportunities that lie ahead.

Core Insights - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative diseases, including Alzheimer's, Parkinson's, and long COVID [4] - The company will host an investor webinar on October 8, 2025, featuring CEO Cuong Do discussing their drug candidate bezisterim (NE3107) and the late-stage orphan drug BIV201 [2][3] Company Overview - BioVie Inc. is developing bezisterim, an orally available small molecule targeting inflammation and insulin resistance, which are key drivers of Alzheimer's, Parkinson's, and long COVID [2][4] - BIV201 is a late-stage orphan drug candidate for refractory ascites, a complication of liver cirrhosis, currently with no FDA-approved therapies [2][4] - The company has received FDA Fast Track status for BIV201 and is in discussions regarding the design of Phase 3 clinical testing [4] Clinical Development - Clinical studies for bezisterim have shown promising results in improving cognition, motor function, and reducing neuroinflammation [2] - BioVie is advancing several late-stage clinical programs and evaluating potential partnerships in markets with significant commercial potential [3]

PART I [Business](index=5&type=section&id=Item%201.%20Business) BioVie Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological, neurodegenerative, and advanced liver diseases, with key drug candidates bezisterim (NE3107) and BIV201 [Neurodegenerative Disease Program](index=5&type=section&id=Neurodegenerative%20Disease%20Program) This program focuses on bezisterim (NE3107), an orally administered small molecule targeting inflammation-driven insulin resistance for Alzheimer's, Parkinson's, and Long COVID - Bezisterim (NE3107) is an investigational, orally administered small molecule targeting inflammation and insulin resistance for Alzheimer's, Parkinson's, and Long COVID treatment[20](index=20&type=chunk)[21](index=21&type=chunk) - A Phase 3 trial for bezisterim in mild-to-moderate Alzheimer's Disease (NCT04669028) was completed, but data was significantly impacted by protocol violations at **15 study sites**, rendering the trial underpowered for its primary endpoints[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk) - A Phase 2 study in Parkinson's Disease (NCT05083260) showed significant improvements in motor control, with a new Phase 2b study for new onset PD commencing in April 2025[22](index=22&type=chunk)[26](index=26&type=chunk)[27](index=27&type=chunk) - The company was awarded a **$13.1 million** grant from the U.S. Department of Defense (DOD) to fund a Phase 2 study (ADDRESS-LC) of bezisterim for neurological symptoms in Long COVID, which began in May 2025[30](index=30&type=chunk)[31](index=31&type=chunk) [Liver Cirrhosis Program](index=7&type=section&id=Liver%20Cirrhosis%20Program) The company is developing BIV201 for ascites in advanced liver cirrhosis, holding FDA Fast Track and Orphan Drug designations, and is finalizing a Phase 3 study protocol - BIV201 is an investigational drug for ascites in advanced liver cirrhosis, granted both FDA Fast Track and Orphan Drug status[35](index=35&type=chunk) - Following a Phase 2 study showing ascites fluid reduction, the company is finalizing a Phase 3 study protocol with a composite primary endpoint for cirrhosis and ascites patients who recovered from acute kidney injury (AKI)[36](index=36&type=chunk)[37](index=37&type=chunk)[40](index=40&type=chunk) - BIV201 features a proprietary, room-temperature stable liquid formulation, with patents granted in the U.S., China, Japan, Chile, and India[36](index=36&type=chunk)[38](index=38&type=chunk) [Intellectual Property](index=9&type=section&id=Intellectual%20Property) BioVie protects its drug candidates, BIV201 and bezisterim (NE3107), through a combination of issued and pending patents in the U.S. and foreign jurisdictions - For BIV201, the company holds Orphan Drug Designations and has been granted patents for its novel liquid formulation in the U.S., India, Chile, China, and Japan[44](index=44&type=chunk) - As of July 31, 2025, the bezisterim (NE3107) portfolio includes **12 issued U.S. patents**, **6 pending U.S. patent applications**, and multiple foreign patents and applications, with some patents expiring as late as 2031[45](index=45&type=chunk)[46](index=46&type=chunk) [Government Regulation](index=10&type=section&id=Government%20Regulation) The company's operations are subject to extensive FDA regulation, involving a lengthy and costly drug approval process with preclinical studies and three phases of clinical trials - The FDA drug approval process involves preclinical tests, an Investigational New Drug (IND) application, and three sequential phases of human clinical trials (Phase 1, 2, and 3)[54](index=54&type=chunk)[61](index=61&type=chunk) - The FDA offers expedited programs like Fast Track, priority review, and accelerated approval for drugs treating serious conditions and unmet medical needs, with BIV201 having Fast Track designation[35](index=35&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) - Orphan Drug Designation, granted to BIV201 for ascites, can provide **seven years** of market exclusivity in the U.S. if it is the first FDA-approved product for the specified rare disease[65](index=65&type=chunk)[66](index=66&type=chunk) [Risk Factors](index=15&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including reliance on third parties, drug development uncertainty, ongoing litigation, lack of revenue, capital needs, and intellectual property challenges [Risks Relating to Our Business and Industry](index=17&type=section&id=Risks%20Relating%20to%20Our%20Business%20and%20Industry) Operational risks include reliance on third-party CROs, financial instability due to no revenue and capital dependence, and ongoing securities litigation related to trial disclosures - The company's reliance on third parties for clinical trials is a major risk, exemplified by significant protocol and cGCP violations at **15 study sites** in the Phase 3 AD trial for bezisterim, rendering it underpowered[80](index=80&type=chunk) - BioVie is subject to a securities class action lawsuit alleging material misrepresentations regarding its Phase 3 AD study, posing financial and reputational risks[85](index=85&type=chunk)[86](index=86&type=chunk) - The company has no approved products, no revenue, and a limited operating history, raising substantial doubt about its ability to continue as a going concern without significant additional funding[88](index=88&type=chunk)[91](index=91&type=chunk)[100](index=100&type=chunk) [Risks Relating to Our Intellectual Property](index=27&type=section&id=Risks%20Relating%20to%20Our%20Intellectual%20Property) Commercial success depends on intellectual property protection, facing risks of patent challenges, invalidation, circumvention, limited global protection, and costly litigation - The company's ability to compete relies on maintaining proprietary technologies, but patents can be challenged, invalidated, or circumvented, and pending applications may not result in issued patents[136](index=136&type=chunk)[137](index=137&type=chunk)[138](index=138&type=chunk) - Patent lifespans are limited and may expire before or shortly after product commercialization, exposing the company to generic competition[157](index=157&type=chunk) - The company may face expensive, time-consuming, and unsuccessful lawsuits to protect its patents or defend against third-party infringement claims[165](index=165&type=chunk)[174](index=174&type=chunk) [Risks Relating to Our Common Stock](index=38&type=section&id=Risks%20Relating%20to%20Our%20Common%20Stock) Common stock investors face significant price volatility, future dilution from equity offerings and warrant exercises, and potential negative impacts from a 1-for-10 reverse stock split - The company's stock price is highly volatile and may fluctuate significantly based on clinical results, analyst recommendations, and market conditions[183](index=183&type=chunk) - Stockholders may experience significant future dilution from potential equity offerings, the exercise of outstanding warrants and options, and share issuances upon achieving clinical and regulatory milestones[185](index=185&type=chunk)[186](index=186&type=chunk)[187](index=187&type=chunk) - The company effected a **1-for-10 reverse stock split** on July 7, 2025, which has caused and could further cause stock price decline and reduced common stock liquidity[189](index=189&type=chunk) [Cybersecurity](index=42&type=section&id=Item%201C.%20Cybersecurity) BioVie's cybersecurity program, managed by an external vendor and overseen by the Audit Committee, protects information systems, with no material threats identified in the last fiscal year - The company's cybersecurity program is managed by an outside vendor, supervised by the CFO, and overseen by the Board's Audit Committee[205](index=205&type=chunk)[206](index=206&type=chunk) - No risks from known cybersecurity threats have materially affected the company in the last fiscal year[206](index=206&type=chunk) [Properties](index=42&type=section&id=Item%202.%20Properties) The company leases its corporate headquarters in Carson City, Nevada, and an additional office in San Diego, California, under separate agreements Properties Leased | Location | Lease Details | | :--- | :--- | | Carson City, NV (HQ) | Annual rent of **$2,200**, one-year term commenced Oct 2022, renewed annually | | San Diego, CA | 60-month term commenced Feb 2024, current monthly rent of **$10,024** with **4% annual increase** | [Legal Proceedings](index=43&type=section&id=Item%203.%20Legal%20Proceedings) BioVie is defending against a consolidated shareholder class action and two derivative lawsuits alleging material misrepresentations regarding its Phase 3 Alzheimer's trial - A consolidated shareholder class action lawsuit alleges material misrepresentations related to the Phase 3 AD trial of bezisterim for securities purchased between December 7, 2022, and November 28, 2023, with the court denying the company's motion to dismiss[210](index=210&type=chunk) - Two shareholder derivative lawsuits making similar allegations have been filed, with one stayed pending the class action suit's motion to dismiss resolution[211](index=211&type=chunk)[212](index=212&type=chunk) PART II [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=44&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For FY2025, BioVie reported a net loss of **$17.5 million**, a significant reduction from **$32.1 million** in FY2024, primarily due to decreased R&D expenses, but faces going concern doubts [Results of Operations](index=47&type=section&id=Results%20of%20Operations) Net loss decreased by **$14.6 million** year-over-year to **$17.5 million** in FY2025, driven by a **$13.8 million** reduction in R&D expenses as clinical trials concluded Selected Statement of Operations Data | Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 | | :--- | :--- | :--- | | **Net Loss** | **$17.5 million** | **$32.1 million** | | Research & Development Expenses | **$9.3 million** | **$23.1 million** | | Selling, General & Administrative Expenses | **$8.6 million** | **$8.8 million** | - The **$13.8 million** decrease in R&D expenses was primarily due to clinical study completion in the prior fiscal year, leading to a net decrease in clinical trial expenses of approximately **$10.8 million**[236](index=236&type=chunk)[237](index=237&type=chunk) [Capital Resources and Liquidity](index=49&type=section&id=Capital%20Resources%20and%20Liquidity) As of June 30, 2025, the company held **$17.5 million** in cash, but recurring losses and negative operating cash flow of **$19.0 million** raise substantial doubt about its going concern ability Selected Financial Position and Cash Flow Data | Metric | As of June 30, 2025 | | :--- | :--- | | Cash and cash equivalents | **$17.5 million** | | Working capital | **$18.4 million** | | Accumulated deficit | **$352.1 million** | | Net cash used in operating activities (FY2025) | **$19.0 million** | - The company's financial condition raises substantial doubt about its ability to continue as a going concern, with future operations dependent on securing additional financing[241](index=241&type=chunk)[243](index=243&type=chunk) - The company raised capital through a **$3.0 million** public offering in September 2024 and **$15.9 million** from three registered direct offerings in October 2024[244](index=244&type=chunk)[245](index=245&type=chunk) [Controls and Procedures](index=50&type=section&id=Item%209A.%20Controls%20and%20Procedures) As of June 30, 2025, management concluded that both disclosure controls and internal control over financial reporting were effective, with no material changes identified - Management concluded that disclosure controls and procedures were effective as of June 30, 2025[252](index=252&type=chunk) - Management concluded that internal control over financial reporting was effective as of June 30, 2025[253](index=253&type=chunk) PART III [Directors, Executive Compensation, Security Ownership, and Other Matters](index=52&type=section&id=Items%2010-14) Information for Items 10 through 14, covering directors, executive compensation, security ownership, related transactions, and accountant fees, is incorporated by reference from the 2025 proxy statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's 2025 Proxy Statement[259](index=259&type=chunk)[260](index=260&type=chunk)[261](index=261&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=53&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists all financial statements and exhibits filed with the Form 10-K report, including corporate governance documents, material contracts, and certifications - This item lists the financial statements and exhibits filed with the report, including agreements, bylaws, and certifications[265](index=265&type=chunk)[266](index=266&type=chunk) Financial Statements and Notes [Report of Independent Registered Public Accounting Firm](index=58&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) The independent auditor's report includes a 'Going Concern' paragraph due to recurring losses and negative cash flows, and identifies 'Research and development expenses and related accruals' as a Critical Audit Matter - The auditor's report contains a 'Going Concern' paragraph, citing recurring losses and negative cash flows from operations as raising substantial doubt about the company's ability to continue[281](index=281&type=chunk) - The audit identified 'Research and development expenses and related accruals' as a Critical Audit Matter due to the high degree of management judgment and subjectivity required[286](index=286&type=chunk)[287](index=287&type=chunk) [Financial Statements](index=60&type=section&id=Financial%20Statements) Financial statements show cash and cash equivalents decreased to **$17.5 million** in FY2025, with net loss improving to **$17.5 million** from **$32.1 million** in FY2024 Selected Balance Sheet Data | Selected Balance Sheet Data (As of June 30) | 2025 | 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | **$17,544,547** | **$23,843,798** | | Total Assets | **$21,562,199** | **$25,208,345** | | Total Liabilities | **$2,550,214** | **$9,702,130** | | Total Stockholders' Equity | **$19,011,985** | **$15,506,215** | Selected Statement of Operations Data | Selected Statement of Operations Data (Year Ended June 30) | 2025 | 2024 | | :--- | :--- | :--- | | Loss from Operations | **$(18,066,200)** | **$(32,179,585)** | | Net Loss | **$(17,542,120)** | **$(32,120,533)** | | Net Loss Per Share (Basic & Diluted)** | **$(12.12)** | **$(73.05)** | Selected Cash Flow Data | Selected Cash Flow Data (Year Ended June 30) | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | **$(19,025,205)** | **$(27,945,024)** | | Net cash provided by financing activities | **$12,725,954** | **$17,802,939** | [Notes to Financial Statements](index=65&type=section&id=Notes%20to%20Financial%20Statements) Notes detail accounting policies, clinical programs, and financial items, including 'Going Concern' uncertainty, related party transactions, equity financings, litigation, and subsequent events - Note 2 reiterates that recurring losses and the need for additional capital raise substantial doubt about the Company's ability to continue as a going concern[316](index=316&type=chunk)[318](index=318&type=chunk) - Note 5 discloses that capital raises triggered down-round features in warrants held by Acuitas, resulting in deemed dividends of **$369,465** in FY2025 and **$886,423** in FY2024[349](index=349&type=chunk) - Note 8 details several equity offerings, including a September 2024 offering that raised approximately **$3.0 million** gross and three October 2024 offerings that raised approximately **$15.9 million** gross[367](index=367&type=chunk)[368](index=368&type=chunk) - Note 14 discloses a subsequent event: on August 11, 2025, the company closed an underwritten public offering, raising net proceeds of approximately **$10.4 million**[407](index=407&type=chunk)

Core Insights - BioVie Inc. is conducting a Phase 2 trial named ADDRESS-LC to evaluate the efficacy of bezisterim for treating Long COVID-related fatigue and cognitive impairment [1][2][10] - Long COVID is recognized as a significant neurological condition affecting approximately 400 million individuals globally, with 6.9% of U.S. adults experiencing it [2] - Bezisterim is an anti-inflammatory agent that targets TLR-driven inflammation, showing promise in treating Long COVID, Alzheimer's disease, and Parkinson's disease [3][8] Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Long COVID [13] - The company’s drug candidate, bezisterim, modulates inflammation and insulin sensitivity, potentially improving clinical outcomes in various neurological conditions [7][13] Trial Design and Funding - The ADDRESS-LC trial is a multicenter, double-blind, randomized, placebo-controlled study, fully funded by a $13.13 million grant from the U.S. Department of Defense [2][12] - The trial incorporates a unique design informed by patient input, aiming to address the unmet needs of Long COVID patients and enhance signal detection for treatment efficacy [4][5] Bezisterim's Mechanism and Clinical Potential - Bezisterim is designed to inhibit TLR4-induced signaling and inflammatory pathways, making it a candidate for reducing neurocognitive symptoms associated with Long COVID [3][10] - The drug has demonstrated a favorable safety and tolerability profile in previous clinical trials for Alzheimer's and Parkinson's diseases [3][9] Key Trial Endpoints - The primary endpoints of the ADDRESS-LC trial include changes in cognitive performance measured by a bespoke Cogstate Cognitive Battery, focusing on symptoms like cognitive impairment and fatigue [5][10]

Core Viewpoint - BioVie Inc. has successfully closed a public offering of 6,000,000 units, raising approximately $12 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit in the offering consisted of one share of common stock and one warrant, priced at $2.00 per unit [1]. - The underwriter exercised an option to purchase an additional 667,300 warrants, increasing the total offering size [1]. - The warrants are immediately exercisable at an exercise price of $2.50 per share and expire five years from issuance [1]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including neurological disorders like Alzheimer's and Parkinson's diseases, as well as liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in neurodegenerative diseases [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].